Anzeige
Erschienen in:
13.06.2017 | Translational Research and Biomarkers
Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer
Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2017
Einloggen, um Zugang zu erhaltenAbstract
Background
Immune checkpoint blockades are currently actively investigated in invasive breast cancers. Given the complexity of immune regulation, multiple inhibitory molecules within the immune checkpoint framework would be involved in tumor immune escape. Evaluation of the components within the framework is a prerequisite for not only identification of additional treatment targets and optimization of immunotherapeutic strategies but also understanding the prognostic value of these molecules.
Methods and Results
We examined a recently described component, herpes virus entry mediator (HVEM), in a large cohort of invasive breast cancers using immunohistochemistry, and evaluated its clinical relevance. HVEM expression was associated with aggressive tumor features, namely high grade (p < 0.001), high pT (p = 0.001) and pN stage (p = 0.008), and was most prevalently found in human epidermal growth factor receptor 2-overexpressed subtype (67%). Interestingly, a negative association with programmed death-ligand 1 (p = 0.021) has been observed. The prognostic impact of HVEM depended on the level of tumor-infiltrating lymphocytes (TILs), with the worst outcome occurring in patients with low TIL, HVEM-positive tumors.
Conclusion
HVEM plays significant oncogenic roles in breast carcinogenesis, and may also be a tumor-specific target.